Conclusions: This initial feasibility and safety study of renal nerve denervation mediated by low and intermediate ␤-radiation dosages indicates that this approach can cause substatntial nerve damage while avoiding significant damage to the renal artery. 
Background: Resistant hypertension is associated with significant cardiovascular morbidity and mortality and it poses a significant treatment challenge for physicians. The treatment of resistant hypertension by renal sympathetic denervation (RD) has demonstrated excellent short-term reductions in blood pressure (BP) at six-months as reported by the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term results will clarify it's durability. Here we assess the long-term results in the first cohort of patients to be treated with RD in Australia.
Methods:
We compared the baseline office-based BP to long-term follow-up office-based BP, number of prescribed anti-hypertensive medications, major adverse cardiac and cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had undergone RD from July 2007 to January 2008. Results: Our cohort had a mean follow-up of 43 months and we found that office-based BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline measurements (pϽ0.003 systolic; pϽ0.09 diastolic). The mean number of prescribed anti-hypertensive medications remained stable throughout the follow-up period (4.88 medications pre-treatment vs 4.1 medications at follow-up; pϭNS). Two patients required hospitalisation for late cerebrovascular events. There were no cardiac events reported. Conclusions: This is the longest reported follow-up of renal sympathetic denervation patients. We have demonstrated a significant and durable decrease in blood pressure. However, there has been no reduction in the number of prescribed anti-hypertensive medications.
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Decrease of the norepinephrine release from sympathetic nerves during renal denervation Background: Renal denervation (RDN) is a promising new treatment option for pronounced hypertension refractory to medical therapy. Interestingly, only 70-80% of patients have a relevant reduction in blood pressure (BP) three to six months after RDN when assessed by systematic 24h BP measurements. No variables have been identified to date predicting the BP response. Methods: We assessed 11 patients with bilateral renal denervation for the changes of preand postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly from the renal artery (RA) and vein (RV). We defined the respective spillover for ⌬NE and ⌬E as the difference RV-RA and compared this difference before and after the procedure. Results: We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA and RV) x 2(pre-and post-procedural)). There was a significant decrease of the ⌬NE RV-RA spill-over comparing pre-with post-procedural levels (184pg/mlϮ180 decrease to 97pg/mlϮ137, Pϭ0.03 for paired t-test). There was no significant change in the epinephrine levels during the procedure under conscious sedation (56pg/mlϮ192 compared to 29pg/mlϮ171, Pϭ0.62 for paired t-test). The pre-post ⌬NE RV-RA was even more pronounced when the median values were compared (P ϭ 0.02).
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Conclusions:
The decrease of NE veno-arterial difference is a directly assessable physiologic marker reflecting the effects of RDN with reduced renal NE release from sympathetic nerves. The current systematic follow-up at 3 and 6 months of our patients will allow the evaluation for a possible association of the pre-post ⌬NE RV-RA with the BP response.
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Ambulatory blood pressure and dipping-pattern after catheter-based renal sympathetic denervation in patients with resistant hypertension Background: Ambulatory blood pressure monitoring (ABPM) is mandatory in every patient with uncontrolled hypertension. Nighttime blood pressure and non-dipping is associated with cardiovascular morbidity and mortality. Catheter-based renal sympathetic denervation (RD) in patients with resistant hypertension has been shown to reduce sympathetic drive and office blood pressure. The influence of RD on ambulatory blood pressure (ABPM) has not been studied in details. Methods: One-hundert patients with resistant hypertension undergoing catheter-based renal denervation were included in the study. Systolic and diastolic blood pressure (SBP/DBP) as well as ABPM (SBP/DBP average, SBP/DBP daytime, SBP/DBP nighttime, heart rate (HR) average) and dipping-pattern were analyzed prior to, and at 3 and 6 months follow-up. Results: RD reduced office SBP and DBP at 3 and 6 months by 22.9/8.1 mmHg and 26.6/9.3 mmHg (p for all Ͻ0.001), respectively. After 3 and 6 months 24-hour average SBP/DBP was reduced by 8.9/4.9 mmHg (pϭ0.019/0.025) and 11.9.5/6.9 mmHg (pϭ0.022/0.011), respectively. Average SBP/DBP were lowered at 3 and 6 months follow-up at daytime by 9.6/5.1 mmHg (pϭ0.010/0.001) and 12.1/8.1 mmHg (pϭ0.001/ 0.001) and at nighttime by 6.6/5.8 mmHg (pϭ0.003/0.005) and 11.3/4.7 mmHg (pϭ0.001/0.001), respectively. Renal denervation also reduced maximum SBP by Ϫ11.9 mmHg at 3 months and by Ϫ14.4 mmHg at 6 months follow-up (pϭ0.009 and 0.006) whereas maximum DBP was not changed. Conclusions: Beside significant reductions in office SBP and DBP, RD also reduced 24-hour average, daytime and nighttime SBP and DBP as well as maximum SBP after 3 and 6 months. Background: Catheter-based selective renal sympathetic denervation has emerged as a new therapeutic option for patients with resistant hypertension. Recent studies have shown that ablation of the renal sympathetic nerves using radiofrequency (RF) energy delivered from within the renal artery is safe and effective. The OneShot™ device (Covidien, Campbell, CA) is a balloon-based RF system using a mounted spiral electrode with a unique feature of irrigation of the vessel lumen during treatment. The non-compliant balloon is inflated under low pressure (1 atm) in the renal artery. The electrode delivers RF energy to ablate adjacent nerve bundles with a single 2-minute treatment.
TCT-212

Methods:
The RHAS study was a single-center feasibility study performed at Mercy Hospital in Auckland, New Zealand. Eligible patients had an office systolic blood pressure (SBP) Ն160 mmHg (Ն150 if diabetic) despite a drug regimen that included two or more antihypertensive medications. Renal artery diameters were 4-7mm. The primary endpoint was the ability to insert the OneShot™ device into each renal artery and deliver RF energy. Secondary endpoints included office SBP at 6 months. Results: Nine patients were enrolled; baseline characteristics and outcomes are shown below. The technical success rate was 88.9%. One failure occurred in the first enrolled patient and was due to an incorrect software setting which inhibited delivery of RF energy. All remaining patients had both renal arteries treated with the OneShot™ device. The mean procedure time (device insertion to end of treatment) was 16 minutes. At 30 days, the mean office SBP was 155 Ϯ 19 mmHg, a change of Ϫ31 Ϯ 14 mmHg. Six-month results are pending.
Characteristic/Outcome
Mean ؎ SD or % (n/N) Change from baseline (mmHg) Ϫ6 Ϯ 10
